In this context, Fu et al. (63) developed a dual-aptamer-functionalised c-MET PROTAC degrader (AS1411-SL1-2), which not only significantly reduced tumour burden but also demonstrated favourable target selectivity and safety. This evidence concerns the gene MET and neoplasm.